Skip to content

CymaBay Therapeutics, Inc.

Delisted

CIK 1042074fmd_06HQ406CYDDZ9WP5Q97DH10ZNMManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Dec 31, 2023, 46 periods

Latest annual · FY2023

Millions
Total revenues
31
Operating income
(102)
Net income
(105)
Free cash flow
(73)

Latest quarter · Q4 FY2023

Millions
Total revenues
0
Operating income
(42)
Net income
(42)
Free cash flow
(28)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2020 to FY2023
n/m
Revenue, 5 yearsFY2018 to FY2023
n/m
Net income, 5 yearsFY2018 to FY2023
n/m

CymaBay Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2023FY2022ChangeSource
Revenue$31.1 million$010-K 2024-02-28 · proof
Operating income-$101.7 million-$93.1 million10-K 2024-02-28 · proof
Net income-$105.4 million-$106 million10-K 2024-02-28 · proof
Cash from operating activities-$72.5 million-$84.1 million10-K 2024-02-28 · proof
Free cash flow-$73 million-$84.2 million10-K 2024-02-28 · proof
Total assets$434.7 million$141.9 million+206.4%10-K 2024-02-28 · proof
Total liabilities$142.4 million$105.7 million+34.8%10-K 2024-02-28 · proof
Cash and cash equivalents$206.5 million$20.3 million+917.9%10-K 2024-02-28 · proof
What was CymaBay Therapeutics, Inc.'s revenue in fiscal 2023?
CymaBay Therapeutics, Inc. reported revenue of $31.1 million for fiscal 2023 (the year ended Dec 31, 2023), against $0 the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was CymaBay Therapeutics, Inc.'s operating income in fiscal 2023?
CymaBay Therapeutics, Inc. reported operating income of -$101.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$93.1 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was CymaBay Therapeutics, Inc.'s net income in fiscal 2023?
CymaBay Therapeutics, Inc. reported net income of -$105.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$106 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was CymaBay Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
CymaBay Therapeutics, Inc. reported cash from operating activities of -$72.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$84.1 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was CymaBay Therapeutics, Inc.'s free cash flow in fiscal 2023?
CymaBay Therapeutics, Inc. reported free cash flow of -$73 million for fiscal 2023 (the year ended Dec 31, 2023), against -$84.2 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What are CymaBay Therapeutics, Inc.'s total assets?
As of Dec 31, 2023, CymaBay Therapeutics, Inc. reported total assets of $434.7 million, against $141.9 million a year earlier (+206.4%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What are CymaBay Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2023, CymaBay Therapeutics, Inc. reported total liabilities of $142.4 million, against $105.7 million a year earlier (+34.8%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What are CymaBay Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2023, CymaBay Therapeutics, Inc. reported cash and cash equivalents of $206.5 million, against $20.3 million a year earlier (+917.9%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1042074&period_type=annual&limit=5"

Information only, not investment advice.